| As one of high-tech industries, technological innovation of Pharmaceutical industry isits source of life, is an inexhaustible motive force corporate earnings. Currently, China isstill in the development stage pharmaceutical manufacturing, R&D funding and R&Dpersonnel are scarce resources, innovative, low efficiency, poor innovation has become thecurrent constraints of the development of China’s pharmaceutical manufacturing industry animportant bottleneck. How to make our country gradually from pharmaceuticalmanufacturers producing country to rely on technological innovation in the pharmaceuticalindustry technology powerhouse, has become a important issue to modern China’spharmaceutical industry. Jingjinji,folllowed China’s Yangtze River Delta, Pearl River Delta,is the third largest after the coastal economic zone. Jingjinji’s regional development in theregion, as well as China’s economic development, has an important strategic impact to theBohai Sea region. therefore, study jingjinji’s pharmaceutical industry technologyinnovation disparities, improve Jingjinji pharmaceutical industry technological innovationcapability of China’s pharmaceutical industry,it has a profound impact to even the Chineseeconomy.In this paper, by using the non-parametric Kruskal-Wallis test method to evaluate thejingjinji’s pharmaceutical industry differences in technological innovation. through thehorizontal comparison of three decades of regional technology innovation indicators, wefound that there are no difference in technological innovation mode and the main differenceis reflected in the efficiency of technological innovation and technical innovation output.for the differences,we are from the institutional, intermediary structure, knowledge baseand other parties to detailed analysis of the reasons for the differences and then point thedirection of jingjinji’s pharmaceutical industry technology innovation and industrialupgrading. |
PDF Full Text Request